Načítá se...
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib. While patients benefit from the use of HER2 inhibitors, many fail therapy and almost all patients become resistant to treatment, indicating a critical need to prevent treatment fail...
Uloženo v:
| Vydáno v: | Breast Cancer Res Treat |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4342830/ https://ncbi.nlm.nih.gov/pubmed/25515931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3227-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|